METHOD AND APPARATUS FOR MEASUREMENT OF WHOLE BLOOD COAGULATION PARAMETERS

The present invention provides a method for determining the coagulation propensity of blood wherein a condition in a portion of a blood sample is assessed and related to the onset of coagulation. Apparatus (12, 14, and 16 together) for performing the method is encompassed by the invention.
| A1 | Albania | ES | Spain
| A2 | Armenia | FI | Finland
| A3 | Austria | FR | France
| A4 | Australia | GA | Gabon
| A5 | Azerbaijan | GB | United Kingdom
| A6 | Bosnia and Herzegovina | GE | Georgia
| A7 | Barbados | GH | Ghana
| A8 | Belgium | GN | Guinea
| A9 | Burkina Faso | GR | Greece
| B1 | Bulgaria | HU | Hungary
| B2 | Benin | IE | Ireland
| B3 | Brazil | IL | Israel
| B4 | Belarus | IS | Iceland
| B5 | Canada | IT | Italy
| B6 | Central African Republic | JP | Japan
| B7 | Congo | KE | Kenya
| B8 | Switzerland | KG | Kyrgyzstan
| B9 | Côte d’Ivoire | KP | Democratic People’s Republic of Korea
| C1 | Cameroon | KR | Republic of Korea
| C2 | China | KZ | Kazakhstan
| C3 | Cuba | LC | Saint Lucia
| C4 | Czech Republic | LI | Liechtenstein
| C5 | Germany | LK | Sri Lanka
| D1 | Denmark | LR | Liberia
| D2 | Estonia | LS | Lesotho
| D3 | Iceland | LT | Lithuania
| D4 | Ireland | LU | Luxembourg
| D5 | Italy | LV | Latvia
| D6 | Japan | MC | Monaco
| D7 | Jordan | MG | Madagascar
| D8 | Jordan | MK | The former Yugoslav Republic of Macedonia
| D9 | Jordan | ML | Mali
| E1 | Egypt | MN | Mongolia
| E2 | Equatorial Guinea | MR | Mauritania
| E3 | Ethiopia | MW | Malawi
| E4 | Eritrea | MX | Mexico
| E5 | Estonia | NE | Niger
| E6 | Ethiopia | NL | Netherlands
| E7 | Finland | NO | Norway
| E8 | France | NZ | New Zealand
| E9 | German Democratic Republic | PL | Poland
| F1 | Finland | PT | Portugal
| F2 | France | RO | Romania
| F3 | Germany | RU | Russian Federation
| F4 | Germany | SD | Sudan
| F5 | Germany | SE | Sweden
| F6 | Germany | SG | Singapore
| F7 | Germany | SI | Slovenia
| F8 | Germany | SK | Slovakia
| F9 | Germany | SN | Senegal
| G1 | Swaziland | SZ | Swaziland
| G2 | Chad | TD | Chad
| G3 | Togo | TG | Togo
| G4 | Tajikistan | TJ | Tajikistan
| G5 | Turkmenistan | TM | Turkmenistan
| G6 | Turkey | TR | Turkey
| G7 | Trinidad and Tobago | TT | Trinidad and Tobago
| G8 | Ukraine | UA | Ukraine
| G9 | Uganda |UG | Uganda
| H1 | United States of America | US | United States of America
| H2 | Uzbekistan | UZ | Uzbekistan
| H3 | Viet Nam | VN | Viet Nam
| H4 | Vietnam | YU | Yugoslavia
| H5 | Zambia | ZM | Zambia
| H6 | Zimbabwe | ZW | Zimbabwe

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.
TITLE: METHOD AND APPARATUS FOR MEASUREMENT OF WHOLE BLOOD COAGULATION PARAMETERS

Field

The present invention relates to measuring and testing and, more particularly, to a method and apparatus for analyzing blood, particularly the coagulation characteristics of whole blood.

Background

Coagulation is the process of clotting, and the phrase "time of coagulation" generally means the time required for a small amount of blood to coagulate. The time of coagulation indicates the propensity of blood to coagulate. It can be determined, and was for many years, by collecting blood in a small container and merely observing elapsed time from the moment the sample was obtained to the time it coagulated. Clearly, this method was not very precise. Coagulation time may also be determined by collecting blood in a small capillary tube, then breaking off short pieces of the tube until threads of fibrin appear between the broken ends. Precision may still be questionable, but coagulation time measured by the latter method is normally six to seventeen minutes.

More precise analyzer technologies that are currently available in hospitals for the assessing coagulation condition are typically found in the hospitals' central laboratories. These analyzers: (1) are usually complex and difficult to operate, requiring trained laboratory technicians; (2) are usually bulky in size and weight; and (3) have moving mechanical parts. Another disadvantage of many available instruments and methods of analysis of whole blood coagulation parameters is that they require separation of plasma from the test sample prior to analysis. As a result, currently available instruments and methods, particularly those used by hospitals in their central laboratories, are not well suited for point of care analysis of whole blood coagulation parameters. Point of care equipment should be (1) compact; (2) simple enough for
operation by nurses or even lay persons; and (3) rugged enough to withstand the rigors of transport from bedside to bedside and use in emergency situations.

U.S. Patents 5,580,744 (Zweig) and 5,418,141 (Zweig et al.) disclose a test article and method for determining coagulation capability in a blood sample. The test article is a porous membrane having a coagulation initiator and substrate impregnated therein. In use, blood is applied to one face of the membrane and plasma is absorbed into the interior of the membrane in the presence of the coagulation initiator and substrate. The membrane produces a detectable signal (i.e., a fluorescent signal) for reading by an automated detector or test system including a timer and means for calculating a coagulation value. Although the disclosed test article is said to be suitable for use in a home setting, as alluded to above, the Zweig test article requires that the plasma be separated from the sample.

U.S. Patent 4,547,735 (Kiesewetter et al.) discloses another example of known apparatus and methods for measuring and testing blood. The disclosed instrument includes two electrodes with which the conductivity of a sample may be measured. The sample contacting faces of the electrodes are placed in vertically separated horizontal planes in an accurately fixed spacing so a blood column of a given size is formed from a sample. Current acts on the sample and the instrument measures change in impedance to determine the hematocrit value of blood. There is no suggestion that the instrument could be used to assess other characteristics or qualities of blood. The instrument is expressly designed to ignore or avoid the effect of sedimenting or aggregating.

U.S. Patent 5,601,995 (Exner) discloses an apparatus and method for detecting coagulation. The method includes providing a porous sheet and applying a blood sample to the sheet so that the blood spreads through a part of the sheet. The spreading extent or spreading rate of the blood in the sheet is visualized, or measured by measuring electrical conductivity across
the sheet, electrical potential across the sheet or an electrical resistance of the sheet. In the visual
or optical embodiment, one measures the extent of area covered by the sample prior to
coagulation, or the rate of growth of the area of the spread sample and tries to extrapolate the
time of coagulation from those observations. In the conductivity embodiment, electrodes are
provided on either side of the porous sheet. The conductivity or electrical impedance between
the electrodes depends on the wetted area between them and, as a sample spreads through the
porous sheet, impedance is reduced and conductivity increased, thereby indicating the extent of
spread in the sheet. In theory, coagulation has occurred when the rate of change in
conductivity/impedance approaches zero. Obviously, in the visual or optical embodiment, one
problem is that mere visual observation may not be very accurate. In either embodiment, the
porous sheet may be affected by ambient conditions and handling, particularly severe problems
if point of care use is attempted.

U.S. Patents 5,298,224 (Plum) and 5,167,145 (Butler et al.) disclose apparatus for
determining blood coagulation time using optical means. The Plum patent discloses the use of
light and light detectors to measure blood transillumination and to determine coagulation time.
The Butler et al. patent discloses the use of an infrared source and a photo detector to measure
electromagnetic transmission and to determine coagulation time.

While the preceding patents reveal advances in the art of evaluating coagulation
parameters or characteristics of blood, none discloses or provides an optimally durable, simple,
portable and reliable apparatus and method for point of care use. Accordingly, there exists a
need for such an analyzer and a method of analysis for accurately and reliably measuring
coagulation characteristics of whole blood.
Summary

The present invention provides a method of assessing the coagulation characteristics of blood. The method involves assessing a condition in a portion of a blood sample and relating the condition to the onset of coagulation. Apparatus for performing the method is encompassed.

In one embodiment, the apparatus includes an electrochemical cell wherein electrodes are positioned in close proximity at the bottom of the cell to make coagulation time measurements of a whole blood sample by measuring electrochemical resistance between the electrodes. By measuring the bottom fraction of the blood, the apparatus detects only resistance changes in the red blood cell fractions and, thus, measures resistance increases caused by the increase in number of red blood cells settling into the area of the electrical field as a function of time. By determining when resistance stops increasing, the onset of coagulation is determined and coagulation time can be determined and/or predicted.

In another embodiment, optically based measurements of the coagulation parameters are made by utilizing a wavelength that is absorbed by red blood cells. A light beam is positioned in an optical path into which red blood cells settle as a function of time. By determining when the light beam wavelength absorption stops increasing, the onset of coagulation is detected.

A clotting reagent may be introduced into a disposable electrochemical or optical cartridge or sample container by incorporating the reagent in the test fluid flow path where they are dissolved into the blood as the sample is introduced into the cartridge. In another embodiment, the reagent may be contained in the sensor (and/or electrode) or light path chamber in a dried form and then dissolved into the sample with blood introduction.

An advantage of such a portable analysis system is that it could be used in hospital settings to characterize patient condition before, during, and after operations where control of coagulation condition is vital to a successful outcome. Another advantage is that this system
could be used in out patient settings, to evaluate patients on anti-coagulant therapies, such as treatment with Warfarin.

Other features and advantages of the present invention will become more fully apparent and understood with reference to the following description and to the appended drawings and claims.

Description of the Drawings

Figure 1 represents blood held in an exemplary sample chamber or container and illustrates the settling of red blood cells in that chamber or container at four different time intervals.

Figure 2 is a side view of a blood sample chamber that includes two spaced electrodes that create an electrical field that reaches the top of the sample chamber.

Figure 3 is a side view of a blood sample chamber that includes two closely spaced electrodes that create an electrical field limited to the bottom area of the sample chamber.

Figure 4 represents blood held in a sample chamber that includes two closely spaced electrodes and illustrates the relationship of the electrical field to the settling of red blood cells in the chamber at four different time intervals.

Figure 5 is a front view of an exemplary optical cell for use in performing an embodiment of the method of the present invention.

Figure 6 is a side view of the optical cell depicted in Figure 5.

Figure 7 represents blood held in the optical cell and illustrates the settling of red blood cells in the chamber at three different time intervals.

Figure 8 is a graph of the change in electrical resistance or light absorbance over time as blood coagulates.
Figure 9 depicts exemplary, experimentally derived results using the optical based coagulation detection method of the present invention.

Figure 10 depicts an exemplary mixing chamber for use with an electrochemical cell.

Figure 11 depicts an exemplary coated reagent sample container for use with an electrochemical cell.

Figure 12 depicts an exemplary mixing chamber for use with an optical cell.

Figure 13 depicts an exemplary coated reagent sample chamber for use with an optical cell.

**Detailed Description of the Invention**

The present invention encompasses a method and apparatus to make coagulation time measurements of a whole blood sample, without separating out the plasma fraction, using an instrument with no moving mechanical parts.

The term “electrochemical cell” is intended to mean a sample material on which electricity acts and at least two electrodes operably coupled to the sample material for communicating electricity to the sample material. Suitable circuit means (wiring, integrated circuits, power source and the like) and control means (a microprocessor, CPU or the like and related software) may be operably incorporated with the cell. As used herein and in the art generally, the term “sensor(s)” is intended to encompass an electrode(s) or a combination of electrodes for analyte measurements, and is intended to be used interchangeably with electrode(s) in any electrochemical embodiment of the present invention. With regard to means for fastening, mounting, attaching or connecting the components of the present invention to form the analyzing device as a whole, unless specifically described as otherwise, such means are intended to encompass conventional connecting mechanisms. Unless specifically otherwise disclosed or
taught, materials for making the components of the present invention may be selected from appropriate materials such as metal, metallic alloys, various plastics and the like.

One example of a component device suitable for use in practicing the electrochemical embodiment of the present invention is the IRMA® device manufactured and sold by Diagnostics Medical, Inc. of Minneapolis, MN. To use the IRMA® device, a sample cartridge suitable for use with the IRMA® device is provided for receiving a sample. The cartridge includes two closely spaced electrodes, approximately 0.003 inches apart, within the device’s cartridge blood flow path. The two electrodes are electrically coupled to the IRMA® device which is programmed to provide a selected current across the electrodes and to measure, record and process a change in resistance. The device may be adapted to assess or monitor resistance and relate a change in resistance to the onset of coagulation, and to provide a time readout (i.e., a coagulation time readout) to an operator. Optionally, other sensors may be situated in the blood flow channel or path for concurrent or separate measurement of other analytes, such as oxygen, carbon dioxide, pH, hematocrit, calcium, potassium, sodium chloride, urea, creatinine or glucose.

In the following description, any references to right and left, top and bottom, upper and lower and horizontal and vertical are to be read and understood with reference to viewing the embodiment of the analyzing unit of the present invention as shown in Figures 3 and 5. Elements or components common to depicted embodiments of the present invention are commonly numbered.

It is well known that the red blood cells in whole blood will settle as a function of time when held in a container 12, as illustrated in Figure 1. At time 1, the cells are dispersed, at times 2 and 3 settling and, at time 4, settled at or near the bottom of the container. The settling process naturally ceases upon the onset of coagulation. The present invention uses this phenomenon to measure the time it takes for the onset of coagulation. In one embodiment, the
present invention take advantage of the fact that resistance between two electrodes in a blood sample is related to the concentration of red blood cells in that sample.

Referring to Figure 2, past attempts to measure coagulation time by electrochemical resistance methods have generally not been as accurate as desired, at least in part because the methods are not specific enough to adequately relate a resistance change to coagulation time. The primary reason is that such methods used electrodes 14, 16 widely spaced from each other, thus measuring total cell resistance as shown in Figure 2. Measuring total cell resistance does not accurately detect resistance changes associated with blood settling, because it does not discriminate between low resistance and high resistance red blood cell fractions or location in the sample chamber.

Referring to Figures 3 and 4, in the apparatus of the present invention the electrodes 14, 16 are positioned close together, in one embodiment approximately 0.003 inches apart, at the bottom of an electrochemical cell or sample chamber 12. The electrical field is thus substantially limited to the bottom fraction of the blood sample and the apparatus detects only resistance changes in the red blood cell fractions and, thus, more accurately measures the resistance increase caused by the increase in number of red blood cells settling into the area of the electrical field as a function of time. By adding a clotting reagent (hereinafter "reagent") to a whole blood sample and determining when resistance stops increasing, the onset of coagulation is detected. This process is visually represented in Figure 3. Red blood cell settling effects have been assessed or quantified using a planar electrode arrangement, utilizing gold or like, generally coplanar electrodes spaced approximately 0.003 inches apart in a cell of 0.025 inch height, using an impedance measurement mode on a typical electrochemical cell or analyzer. While a .003 space between electrodes is used in one embodiment, the space may range approximately
between 0.0001 and 0.0500 of an inch apart, and may be optimized according to the selected size of the sample containing chamber.

The method of the present invention, assessing a condition in a region or portion of a sample to quantify or characterize another condition or characteristic of the whole sample, may be adapted to use optically based measurements. For example, using a light source which generates a wavelength that is absorbed by red blood cells, and positioning the light beam from the source in an optical path into which red blood cells settle as a function of time, it can be determined when the settling of red blood cells ceases, i.e., when the change in absorption slows or stops, the lapsed time may be related to the onset of coagulation. Figures 5 and 6 depict an exemplary optical cell. Figure 7 illustrates the optical path and changes that occur as the red blood cells of a whole blood sample settle.

Figure 8 graphically illustrates how changes in resistance or absorbance can be related to coagulation and Figure 9 presents exemplary, experimentally derived results using the optical based detection method.

A suitable reagent (e.g., prothrombin, thrombin, thromboplatin, calcium, fibrinogen or the like), which may be necessary for most coagulation measurements, can be introduced into a disposable electrochemical or optical cartridge by incorporating them in the fluid flow path, where they are dissolved into the blood as the sample is introduced into the cartridge. Examples of reagent mixing methodologies are represented in Figures 10 and 11 for electrochemical cells, and in Figures 12 and 13 for optical cells. In one method (Figures 10 and 12), the reagent is introduced via a premixing chamber prior to blood passing over the electrodes or into the light path. In another method (Figures 11 and 13), the reagent is contained in the electrode or light path chamber in a dried form, then dissolved into the sample with blood introduction. The reagents should be dissolved into the blood sample completely and quickly, so that reagent
dissolution time will not adversely impact clotting time. For example, freeze drying reagents
directly in an optical cell of 100 micron thickness, 1.8 cm width, and 5 cm height adequately
served to enable measurement of red blood cell settling and coagulation onset, using a
conventional laboratory spectrophotometer.

Reagents and their concentrations used are those typically associated with clotting
measurements. For example, in the optical cell described above, a reagent deposit of
thromboplastin and calcium can be used to determine the prothrombin time coagulation
measurement.

Additionally, titration type measurements can be made using multiple cuvettes, or
a single cuvette with multiple path chambers. For example, to characterize the heparin
concentration of a blood sample, several cells of varying protamine concentration can be used to
measure coagulation response to varying protamine doses. Thus, the protamine dosage to be
administered to a patient can be quickly and easily determined.

Although a description of the invention has been presented, various embodiments,
including those mentioned above, could be made or performed without deviating from the spirit
of the present invention. It is desired, therefore, that reference be made to the appended claims
rather than to the foregoing description to indicate the scope of the invention.
Claims

What is claimed is:

1. An analyzer for determining the coagulation condition of blood comprising:
   a blood sample;
   two electrodes in close proximity to each other;
   means for providing current to the electrodes, wherein the current passes from one said
   electrode to the other through a portion of the blood sample; and
   means for measuring a change in resistance as the current passes through the portion of
   the blood sample.

2. The analyzer according to claim 1, wherein a change in resistance between the electrodes
   relates to the coagulation condition of the sample.

3. The analyzer according to claim 2, wherein the electrodes are between 0.001 and 0.0500 of an
   inch apart.

4. The analyzer according to claim 2, wherein the electrodes are 0.003 of an inch apart.

5. The analyzer according to claim 2, further comprising a controller operably coupled to the
   means for providing current to the electrodes.

6. A method of assessing the coagulation propensity of blood comprising the steps of:
   providing a blood sample;
   assessing a condition in a portion of the blood sample; and
   relating the condition to the coagulation propensity of the blood sample.

7. The method according to claim 6, wherein the condition is the concentration of red blood cells
   in the portion.

8. The method according to claim 7, wherein the concentration is related to the settling of red
   blood cells into the portion.
9. The method according to claim 8, further comprising relating the time it takes said settling to cease to the onset of coagulation.

10. A method of measuring coagulation time by monitoring electrochemical resistance in a sample wherein a resistance change is related to coagulation time.

11. The method according to claim 10, further comprising providing a blood sample and two electrodes, passing a current between the electrodes and through a portion of the sample.

12. The method according to claim 11, wherein the portion of the sample is a bottom fraction thereof.

13. A method of measuring coagulation time optically wherein a light beam is directed into an optical path into which red blood cells settle over time.

14. The method according to claim 13, further comprising relating the time it takes said settling to occur to the onset of coagulation.
Fig. 1
**INTERNATIONAL SEARCH REPORT**

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : G01N 27/26, 33/00, 33/88  
US CL. : 205/792; 204/403; 422/73; 436/69.70

According to international Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 205/792; 204/403; 422/73; 436/69.70

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>US 3,840,806 A (STONER ET AL) 08 October 1974 (08-10-74), abstract; column 2, lines 56 - column 3, line 22; column 5, lines 24-27; column 7, lines 64-67; claim 9; and Figures 2, 3A, 3B, 7, and 9.</td>
<td>1, 2, 5, 6, 10-12</td>
</tr>
<tr>
<td>Y</td>
<td>US 5,385,846 A (KUHN ET AL) 31 January 1995 (31-01-95), figure 2, column 3, lines 6-8; column 4, lines 3, 4, and 47-52; and column 6, lines 35-42.</td>
<td>3, 4</td>
</tr>
<tr>
<td>X</td>
<td>WPIDS abstract of SU 1503014 A (G. G. FEDOROV) 23 August 1989 (23-08-89), abstract.</td>
<td>1, 2, 6, 10, 11</td>
</tr>
</tbody>
</table>

[ ] Further documents are listed in the continuation of Box C.  See patent family annex.

* Special categories of cited documents:
  *A* document defining the general state of the art which is not considered to be of particular relevance
  *B* earlier document published on or after the international filing date
  *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  *O* document referring to an oral disclosure, use, exhibition or other means
  *P* document published prior to the international filing date but later than the priority date claimed

* T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

* X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

* Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

* A* document member of the same patent family

**Date of the actual completion of the international search**

18 MAY 1998

**Date of mailing of the international search report**

23 JUN 1998

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231  
Facsimile No. (703) 305-3230

Authorized officer  
ALEXANDER NOGUEROLA

Telephone No. (703) 308-0661

Form PCT/ISA/210 (second sheet) (July 1992)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WPIDS abstract of SU 1239589 A (MROCHEK ET AL) 23 June 1986 (23-06-86), abstract and figure.</td>
<td>1, 2, 6, 10, 11</td>
</tr>
<tr>
<td>Y</td>
<td>SU 1239589 A (MROCHEK ET AL) 23 June 1986 (23-06-86), figure.</td>
<td>3, 4</td>
</tr>
<tr>
<td>X</td>
<td>EP 582431 A2 (KOWA COMPANY LTD) 02 September 1994 (02-09-94), abstract; column 1, lines 1-54; and figures 1 and 4A.</td>
<td>12</td>
</tr>
<tr>
<td>Y</td>
<td></td>
<td>13</td>
</tr>
</tbody>
</table>

Form PCT/ISA/210 (continuation of second sheet)(July 1992)*
B. FIELDS SEARCHED
Electronic data bases consulted (Name of data base and where practicable terms used):

APS, WPI, CAPLUS, JAPIO